Clinical trials: COPD - Chronic Obstructive Pulmonary Disease
- Condition COPD - Chronic Obstructive Pulmonary Disease
- Funder type Industry (pharma, biotech, devices)
Pulmonary Disease, Chronic Obstructive
Safety Study Using GSK573719 And Tiotropium In Patients With Chronic Obstructive Pulmonary Disease
GSK573719 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for once daily treatment of chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT00515502
- Testing
- GSK573719, Tiotropium
- Where
- 3 sites in Germany
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Change in Symptom and Quality of Life in COPD by Budesonide/Glycopyrronium/Formoterol Fumarate Pressurized Metered Dose Inhaler (BGF pMDI)
This study is primarily aimed to investigate whether PROs can be improved after the initiation of BGF pMDI in real world clinical settings.
- Trial name
- EBISU (NCT05219630)
- Where
- 17 sites in Japan
- Volunteers
- 106 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks
This 12-week study evaluated the efficacy and safety of indacaterol versus placebo.
- Trial name
- NCT01068600
- Testing
- Indacaterol
- Where
- 54 sites in United States
- Volunteers
- 318 people
- Sponsor
- Novartis
Pulmonary Disease, Chronic Obstructive
Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
The objective of this study is to evaluate the efficacy and safety of 12 weeks treatment with tiotro pium HandiHaler® 18 mcg daily compared to Combivent® MDI CFC Inhalation Aerosol 2 actuations qid in COPD patients currently…
- Trial name
- NCT00388882
- Testing
- tiotropium, ipratropium bromide / albuterol
- Where
- 40 sites in United States, Argentina and 3 more
- Volunteers
- 327 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
High Dose Trial in COPD
The primary objective of this study was to compare the efficacy and safety of 200 μg and 400 μg of BEA 2180 BR to tiotropium 5 μg and placebo when each was delivered by the Respimat® Inhaler once daily for four weeks in patients…
- Trial name
- NCT00128440
- Testing
- BEA 2180 BR, tiotropium
- Where
- 13 sites in United States
- Volunteers
- 78 people
- Sponsor
- Boehringer Ingelheim
COPD
Portable Oxygen Concentrator Improvements to Physical Activity, Oxygen Usage, and Quality of Life in Chronic Obstructive Pulmonary Disease Patients Using Long-term Oxygen Therapy (POC-STEP)
To evaluate changes in activity based on the use of portable oxygen concentrators combined with standard of care (SOC) long- term oxygen therapy versus SOC long-term oxygen therapy alone at 12 weeks in patients with COPD who…
- Trial name
- POC-STEP (NCT03513068)
- Testing
- Portable Oxygen Concentrator (POC)
- Where
- 11 sites in United States
- Volunteers
- 108 people
- Sponsor
- ResMed
Chronic Obstructive Pulmonary Disease
Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients
The primary purpose of the study is to investigate if Symbicort is more effective than Oxis in increasing forced expiratory volume in one second (FEV1), measured at the clinics, in patients with COPD.
- Trial name
- SUMIRE (NCT01069289)
- Testing
- Budesonide/formoterol (Symbicort Turbuhaler), Formoterol (Oxis Turbuhaler)
- Where
- 119 sites in India, Japan and 7 more
- Volunteers
- 1,293 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
The overall objective of this study is to assess the efficacy and safety of 52 weeks once daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT Inhaler) compared with the individual components…
- Trial name
- NCT01431287
- Testing
- tiotropium + olodaterol, tiotropium, olodaterol
- Where
- 240 sites in United States, Austria and 22 more
- Volunteers
- 2,539 people
- Sponsor
- Boehringer Ingelheim
COPD
Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD Subjects
This study is designed to investigate the safety, tolerability and pharmacokinetics of inhaled CHF6523 DPI in healthy male subjects first and then in COPD subjects after single or repeated dosesof CHF6523.
- Trial name
- CHF6523 (NCT04032535)
- Testing
- CHF6523
- Where
- United Kingdom
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Pulmonary Disease, Chronic Obstructive
Free Combinations of Tiotropium Inhalation Powder Capsule + Salmeterol Metered Dose Inhaler, Tiotropium Inhalation Powder Capsule and Salmeterol Metered Dose Inhaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Main Study: To evaluate and to compare the lung function response to the free combinations of tiotropium 18 μg (QD) + salmeterol 50 μg (QD or BID), salmeterol 50 μg BID and tiotropium 18 μg QD at the end of 6-week treatment…
- Trial name
- NCT02242253
- Testing
- Tiotropium, Salmeterol
- Volunteers
- 97 people
- Sponsor
- Boehringer Ingelheim
Emphysema
STRIVE Post-Market Registry Study
This is a single-arm, prospective, multi-center, Registry study to evaluate the long-term safety and effectiveness of the Spiration Valve System (SVS) for the treatment of severe emphysema in a post-market setting.
- Trial name
- NCT04302272
- Testing
- Spiration Valve System (SVS)
- Where
- 16 sites in United States
- Volunteers
- 150 people
- Sponsor
- Olympus Corporation of the Americas
Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
The purpose of the study is to investigate the efficacy of galvokimig versus placebo in the time to the first acute exacerbation of chronic obstructive pulmonary disease (AECOPD) in study participants with moderate-to-severe COPD…
- Trial name
- SCALA (NCT07725939)
- Testing
- Galvokimig
- Where
- 23 sites in United States, China
- Volunteers
- 402 people
- Sponsor
- UCB Biopharma SRL
Chronic Obstructive Pulmonary Disease (COPD)
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)
- Trial name
- EMBARK (NCT06883305)
- Testing
- Tezepelumab
- Where
- 305 sites in United States, Brazil and 16 more
- Volunteers
- 990 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease
The primary objective of this study was to compare the long-term (12-week) bronchodilator efficacy and safety of ipratropium bromide / salbutamol combination administered by the Respimat® 40 mcg / 200 mcg (one inhalation q.i.d.)…
- Trial name
- NCT02177253
- Testing
- Ipratropium bromide / Salbutamol, Ipratropium bromide, COMBIVENT Inhalation Aerosol
- Volunteers
- 1,118 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Airways Disease
Tolerability, efficacy and handling of Berodual® Respimat® 20/50µg/dose solution for inhalation in patients with chronic obstructive airways disease in daily practice
- Trial name
- NCT02231372
- Testing
- Berodual® Respimat® solution for inhalation
- Volunteers
- 4,602 people
- Sponsor
- Boehringer Ingelheim
COPD, Dyspnea
Vitabreath Pilot in Chronic Obstructive Pulmonary Disease (COPD) Patients
Dyspnea is the most common symptom limiting the ability of COPD patients to perform activities of daily living. Although there has been research involving the benefit of providing Non Invasive Ventilation (NIV) during exercise to…
- Trial name
- NCT03349437
- Testing
- Vitabreath Device, Pursed Lip Breathing
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Philips Respironics
COPD Exacerbation, COPD
Telemonitoring System for Early Diagnosis of COPD Exacerbations.
A tailored management of COPD patients would obviously allow to reduce costs for hospitalizations and improve quality of life. This management could benefit of the Information and Comunication Technology support, which can offer…
- Trial name
- NCT03739957
- Testing
- BPCO Media Kit
- Where
- 3 sites in Italy
- Volunteers
- 500 people
- Sponsor
- Laboratori di Informatica Applicata
COPD
Study to Evaluate the Impact of the "PROactive Telecoaching Program" on Physical Activity in Patients With COPD.
This study will test two instruments to measure physical activity in COPD patients: A questionnaire and two small physical activity monitors .Patients will be randomized to either receive the telecoaching program in addition to…
- Trial name
- PROactive (NCT01992081)
- Testing
- Automated telehealth system, Usual care
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD
This study is designed to evaluate the effect of fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) Inhalation Powder once daily (QD) on arterial stiffness compared with Tiotropium QD over 12 week treatment period in…
- Trial name
- NCT01395888
- Testing
- fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI), Tiotropium
- Where
- 55 sites in Argentina, France and 5 more
- Volunteers
- 260 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease
Dose Ranging Study of Glycopyrronium Bromide in Patients With Moderate or Severe Chronic Obstructive Pulmonary Disease
This is an investigation of the beneficial effects, tolerability and safety of a range of single doses of orally inhaled glycopyrronium bromide (PSX1002GB pMDI) in male and female patients with moderate or severe chronic…
- Trial name
- NCT01703624
- Testing
- glycopyrronium bromide
- Where
- United Kingdom
- Volunteers
- 37 people
- Sponsor
- Prosonix Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.